Search

Your search keyword '"Markus Joerger"' showing total 22 results

Search Constraints

Start Over You searched for: Author "Markus Joerger" Remove constraint Author: "Markus Joerger" Journal journal of clinical oncology Remove constraint Journal: journal of clinical oncology
22 results on '"Markus Joerger"'

Search Results

1. MVX-ONCO-1 in advanced refractory cancers: Safety, feasibility, and preliminary efficacy results from all HNSCC patients treated in two ongoing clinical trials

2. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study

3. Phase Ib study of the anti-TGF-β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors

4. SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial

5. Pharmacokinetics, safety, and early activity of a nanoparticle micellar formulation of docetaxel in women with metastatic breast cancer: Results of two randomized trials (phase I and II)

6. Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on FGFR mRNA overexpression

7. Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels

8. Phase 1/2a study of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors

9. Circulating Deoxyribonucleic Acid As Prognostic Marker in Non–Small-Cell Lung Cancer Patients Undergoing Chemotherapy

10. Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors

11. Patient selection using novel RNA-based approaches: Early experience from a phase I study with the pan-FGFR inhibitor BAY 1163877 in patients with urothelial bladder cancer

12. Prospective study evaluating the effect of impaired tamoxifen metabolisation on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting

13. A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results

14. Time of referral of patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell cancer (HNSCC) to medical oncology and survival

15. Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC)

16. CYPTAM-BRUT 2: A prospective multicenter observational study in the neoadjuvant and metastatic setting investigating tamoxifen response between women with a favorable versus unfavorable endoxifen profile

17. Drug pathway–associated gene polymorphisms in patients with advanced non-small cell lung cancer receiving first-line platinum-gemcitabine combination chemotherapy: A prospective multicenter observational study

18. Lenalidomide in solid tumor patients with inflammatory cancer cachexia: A multicenter, randomized, double-blind, proof-of-concept study of fixed dose or CRP-response-guided dose or placebo

19. Predictive value of n-terminal telopeptide of type I collagen in patients with malignant osteolytic bone disease on bisphosphonates

20. Pharmacology of high-dose methotrexate in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG #20 trial

21. Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC-PAMM-NDDG

22. Serum proteomic profiling of advanced gastric cancer and identification of proteomic changes following response to epirubicin, cisplatin and capecitabine chemotherapy as diagnostic and predictive biomarkers

Catalog

Books, media, physical & digital resources